Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Med Microbiol ; 67(12): 1689-1697, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30307842

RESUMO

PURPOSE: Clostridium difficile is an anaerobic spore-forming bacterial pathogen that causes a spectrum of illness severity ranging from mild diarrhoea to severe life-threatening pseudomembranous colitis. C. difficile infection (CDI) is antibiotic-associated and primarily mediated by two exotoxins, Toxins A and B. We and others have shown that some antibiotics stimulate Toxin A and B production by C. difficile in a strain-specific manner. Still, the effects of newer anti-C. difficile antibiotics on this process and spore formation remain to be investigated. METHODOLOGY: Surotomycin (formally CB-183,315) is a novel, minimally absorbed, narrow-spectrum antibiotic. We determined the effects of surotomycin on C. difficile growth, toxin production and sporulation in historical and BI/NAP1/027 epidemic strains of C. difficile.Results/Key findings. While antibiotic free controls showed toxin production during the stationary phase growth, all strains exposed to sub-inhibitory concentrations of surotomycin and vancomycin demonstrated increased TcdA and TcdB production during early (log phase) growth by all strains. However, this effect was not observed at 24 or 48 h post-treatment by any of the C. difficile strains exposed to either antibiotic. Additionally, all doses of surotomycin and vancomycin suppressed spore formation in all tested strains. CONCLUSION: In summary, these findings demonstrate that surotomycin and vancomycin have similar effects on exotoxin production and sporulation by C. difficile in vitro. Furthermore, since spores contribute to recurrent infection, the ability of surotomycin to suppress spore formation may explain its ability to disrupt the reinfection cycle in the clinical setting.


Assuntos
Antibacterianos/farmacologia , Clostridioides difficile/efeitos dos fármacos , Clostridioides difficile/metabolismo , Lipopeptídeos/farmacologia , Peptídeos Cíclicos/farmacologia , Vancomicina/farmacologia , Fatores de Virulência/metabolismo , Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos , Lipopeptídeos/administração & dosagem , Testes de Sensibilidade Microbiana , Peptídeos Cíclicos/administração & dosagem , Fatores de Tempo , Vancomicina/administração & dosagem , Fatores de Virulência/genética
2.
Int J Antimicrob Agents ; 52(4): 469-473, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30012441

RESUMO

Clostridium septicum is a highly pathogenic microbe that causes gas gangrene in humans, and is the principal cause of spontaneous gas gangrene in patients with gastrointestinal maladies, including adenocarcinoma of the colon. Despite modern approaches to manage C. septicum infection, morbidity and mortality remain high (>60%). At present, no objective in-vivo data exist supporting the current antibiotic treatment recommendations for C. septicum infection. Utilizing an established murine model of clostridial myonecrosis, this study investigated the efficacy of standard antibiotics for anaerobic Gram-positive soft tissue infections (penicillin, clindamycin, tetracycline and vancomycin) in treating C. septicum gas gangrene. Following intramuscular challenge with 1 × 106 colony-forming units of C. septicum, antibiotics were administered by intraperitoneal injection every 4 h for a total of four doses. At 30 h, all animals in all treatment groups survived the C. septicum challenge, compared with no survivors in the untreated controls (100% mortality by 10 h). However, by 60 h, mice treated with vancomycin exhibited 40% mortality, with no mortality observed in any other antibiotic treatment group. Microbroth dilution minimum inhibitory concentration analyses for three strains of C. septicum also demonstrated high susceptibility to penicillin, clindamycin and tetracycline, but considerably lower susceptibility to vancomycin. This study suggests that penicillin, clindamycin and tetracycline are suitable alternatives for the treatment of C. septicum infection in humans.


Assuntos
Antibacterianos/farmacologia , Clindamicina/farmacologia , Infecções por Clostridium/tratamento farmacológico , Clostridium septicum/efeitos dos fármacos , Penicilinas/farmacologia , Infecções dos Tecidos Moles/tratamento farmacológico , Tetraciclina/farmacologia , Animais , Infecções por Clostridium/microbiologia , Infecções por Clostridium/patologia , Clostridium septicum/crescimento & desenvolvimento , Clostridium septicum/patogenicidade , Esquema de Medicação , Feminino , Humanos , Injeções Intramusculares , Injeções Intraperitoneais , Camundongos , Testes de Sensibilidade Microbiana , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/microbiologia , Músculo Esquelético/patologia , Infecções dos Tecidos Moles/microbiologia , Infecções dos Tecidos Moles/patologia , Análise de Sobrevida , Vancomicina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA